Golimumab in patients with active rheumatoid arthritis despite treatment with methotrexate: A randomized, double-blind, placebo-controlled, dose-ranging study

Arthritis and Rheumatism

Volumn 58, Issue 4, 2008, Pages 964-975

  Kay, Jonathan ^a   Matteson, Eric L ^b   Dasgupta, Bhaskar ^c   Nash, Peter ^d,e   Durez, Patrick ^f   Hall, Stephen ^g   Hsia, Elizabeth C ^h,i   Han, John ^h   Wagner, Carrie ^h   Xu, Zhenhua ^h   Visvanathan, Sudha ^h   Rahman, Mahboob U ^h,i  

^a MASSACHUSETTS GENERAL HOSPITAL   (United States)

^b Mayo Clinic   (United States)

^c SOUTHEND UNIVERSITY HOSPITAL   (United Kingdom)

^d NAMBOUR GENERAL HOSPITAL   (Australia)

^e UNIVERSITY OF QUEENSLAND   (Australia)

^f CLINIQUES UNIVERSITAIRES SAINT LUC   (Belgium)

^g CABRINI INSTITUTE   (Australia)

^h CENTOCOR INC   (United States)

ⁱ UNIVERSITY OF PENNSYLVANIA   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ALANINE AMINOTRANSFERASE; ANTIBODY; ANTINUCLEAR ANTIBODY; CORTICOSTEROID DERIVATIVE; DISEASE MODIFYING ANTIRHEUMATIC DRUG; FOLIC ACID; GOLIMUMAB; INFLIXIMAB; METHOTREXATE; NONSTEROID ANTIINFLAMMATORY AGENT; PLACEBO;

ADULT; AGED; ALANINE AMINOTRANSFERASE BLOOD LEVEL; ANTIBODY RESPONSE; ARTICLE; BACTERIAL INFECTION; BASAL CELL CARCINOMA; CHRONIC OBSTRUCTIVE LUNG DISEASE; CLINICAL TRIAL; CONGESTIVE HEART FAILURE; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DOUBLE BLIND PROCEDURE; DRUG BLOOD LEVEL; DRUG EFFICACY; DRUG FATALITY; DRUG INDUCED HEADACHE; DRUG SAFETY; DRUG WITHDRAWAL; ENTEROCOLITIS; FEMALE; FRACTURE; HEART TAMPONADE; HUMAN; HYPERGLYCEMIA; INFECTION; INGUINAL HERNIA; INJECTION SITE BLEEDING; INJECTION SITE BURNING; INJECTION SITE ERYTHEMA; INJECTION SITE INDURATION; INJECTION SITE PAIN; INJECTION SITE PRURITUS; INJECTION SITE SWELLING; INJECTION SITE URTICARIA; LUNG ADENOCARCINOMA; LUNG CANCER; MAJOR CLINICAL STUDY; MALE; MULTICENTER STUDY; NAUSEA; PERIPHERAL OCCLUSIVE ARTERY DISEASE; PNEUMONIA; PRIORITY JOURNAL; PYELONEPHRITIS; RANDOMIZED CONTROLLED TRIAL; RESPIRATORY TRACT INFECTION; RHEUMATOID ARTHRITIS; SEPSIS; SEPTIC SHOCK; SIDE EFFECT; SINUSITIS; SQUAMOUS CELL CARCINOMA; STATISTICAL SIGNIFICANCE; STEADY STATE; STREPTOCOCCUS INFECTION; SUPERFICIAL THROMBOPHLEBITIS; TREATMENT RESPONSE;

AGED; ANTIBODIES, MONOCLONAL; ANTIRHEUMATIC AGENTS; ARTHRITIS, RHEUMATOID; DOSE-RESPONSE RELATIONSHIP, DRUG; DOUBLE-BLIND METHOD; DRUG RESISTANCE; FEMALE; HUMANS; IMMUNOLOGIC FACTORS; MALE; METHOTREXATE; MIDDLE AGED; SEVERITY OF ILLNESS INDEX;

EID: 42449157502     PISSN: 00043591     EISSN: None     Source Type: Journal    
DOI: 10.1002/art.23383     Document Type: Article

References (17)

1. Moreland LW, Schiff MH, Baumgartner SW, Tindall EA, Fleischmann RM, Bulpitt KJ, et al. Etanercept therapy in rheumatoid arthritis: a randomized, controlled trial. Ann Intern Med 1999;130:478-86.
2. Lipsky PE, van der Heijde DM, St.Clair EW, Furst DE, Breedveld FC, Kalden JR, et al, for the Anti-Tumor Necrosis Factor Trial in Rheumatoid Arthritis with Concomitant Therapy Study Group. Infliximab and methotrexate in the treatment of rheumatoid arthritis. N Engl J Med 2000;343:1594-602.
3. Weinblatt ME, Keystone EC, Furst DE, Moreland LW, Weisman MH, Birbara CA, et al. Adalimumab, a fully human anti-tumor necrosis factor α monoclonal antibody, for the treatment of rheumatoid arthritis in patients taking concomitant methotrexate: the ARMADA trial. Arthritis Rheum 2003;48:35-45.
4. Shealy D, Cai A, Lacy E, Nesspor T, Staquet K, Johns L, et al. Characterization of golimumab (CNTO 148), a novel fully human monoclonal antibody specific for TNF-α [abstract]. Ann Rheum Dis 2007;66(Suppl II):151.
5. Arnett FC, Edworthy SM, Bloch DA, McShane DJ, Fries JF, Cooper NS, et al. The American Rheumatism Association 1987 revised criteria for the classification of rheumatoid arthritis. Arthritis Rheum 1988;31:315-24.
6. Fries JF, Spitz P, Kraines RG, Holman HR. Measurement of patient outcome in arthritis. Arthritis Rheum 1980;23:137-45.
7. Felson DT, Anderson JJ, Boers M, Bombardier C, Furst D, Goldsmith C, et al. American College of Rheumatology preliminary definition of improvement in rheumatoid arthritis. Arthritis Rheum 1995;38:727-35.
8. Prevoo ML, van 't Hof MA, Kuper HH, van Leeuwen MA, van de Putte LB, van Riel PL. Modified disease activity scores that include twenty-eight-joint counts: development and validation in a prospective longitudinal study of patients with rheumatoid arthritis. Arthritis Rheum 1995;38:44-8.
9. Van Gestel AM, Haagsma CJ, van Riel PL. Validation of rheumatoid arthritis improvement criteria that include simplified joint counts. Arthritis Rheum 1998;41:1845-50.
10. Prevoo ML, van Gestel AM, van 't Hof MA, van Rijswijk MH, van de Putte LB, van Riel PL. Remission in a prospective study of patients with rheumatoid arthritis: American Rheumatism Association preliminary remission criteria in relation to the disease activity score. Br J Rheumatol 1996;35:1101-5.
11. Bathon JM, Martin RW, Fleischmann RM, Tesser JR, Schiff MH, Keystone EC, et al. A comparison of etanercept and methotrexate in patients with early rheumatoid arthritis. N Engl J Med 2000;343:1586-93.
12. Schiff M, Weaver A, Keystone E, Moreland L, Spencer-Green G. Comparison of ACR response, numeric ACR, and ACR AUC as measures of clinical improvement in RA clinical trials [abstract]. Arthritis Rheum 1999;42 Suppl 9:S81.
13. Clark M. Antibody humanization: a case of the 'Emperor's new clothes'? Immunol Today 2000;21:397-402.
14. Pendley C, Schantz A, Wagner C. Immunogenicity of therapeutic monoclonal antibodies. Curr Opin Mol Ther 2003;5:172-9.
15. Bender NK, Heilig CE, Droll B, Wohlgemuth J, Armbruster FP, Heilig B. Immunogenicity, efficacy and adverse events of adalimumab in RA patients. Rheumatol Int 2007;27:269-74.
16. Bartelds GM, Wijbrandts CA, Nurrnohamed MT, Stapel S, Lems WF, Aarden L, et al. Clinical response to adalimumab: relationship to anti-adalimumab antibodies and serum adalimumab concentrations in rheumatoid arthritis. Ann Rheum Dis 2007;66:921-6.
17. Westhovens R, Yocum D, Han J, Berman A, Strusberg I, Geusens P, et al, for the START Study Group. The safety of infliximab, combined with background treatments, among patients with rheumatoid arthritis and various comorbidities: a large, randomized, placebo-controlled trial. Arthritis Rheum 2006;54:1075-86.